Published in J Clin Oncol on August 22, 2011
Drug development and clinical trials--the path to an approved cancer drug. Nat Rev Clin Oncol (2012) 4.98
Lineage analysis of basal epithelial cells reveals their unexpected plasticity and supports a cell-of-origin model for prostate cancer heterogeneity. Nat Cell Biol (2013) 2.90
Characterization of 1577 primary prostate cancers reveals novel biological and clinicopathologic insights into molecular subtypes. Eur Urol (2015) 1.80
DNA methylation alterations exhibit intraindividual stability and interindividual heterogeneity in prostate cancer metastases. Sci Transl Med (2013) 1.63
Effect of Carotene and Lycopene on the Risk of Prostate Cancer: A Systematic Review and Dose-Response Meta-Analysis of Observational Studies. PLoS One (2015) 1.48
Development and validation of a scalable next-generation sequencing system for assessing relevant somatic variants in solid tumors. Neoplasia (2015) 1.44
Whole-genome plasma sequencing reveals focal amplifications as a driving force in metastatic prostate cancer. Nat Commun (2016) 1.44
Oncogene-mediated alterations in chromatin conformation. Proc Natl Acad Sci U S A (2012) 1.40
ETV4 promotes metastasis in response to activation of PI3-kinase and Ras signaling in a mouse model of advanced prostate cancer. Proc Natl Acad Sci U S A (2013) 1.26
SPOP Promotes Ubiquitination and Degradation of the ERG Oncoprotein to Suppress Prostate Cancer Progression. Mol Cell (2015) 1.25
Prostate cancer in East Asia: evolving trend over the last decade. Asian J Androl (2015) 1.22
Prostate cancer-associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4. Nat Med (2017) 1.21
Clinical potential of the ERG oncoprotein in prostate cancer. Nat Rev Urol (2012) 1.17
Genomic profiling defines subtypes of prostate cancer with the potential for therapeutic stratification. Clin Cancer Res (2013) 1.16
Advancing precision medicine for prostate cancer through genomics. J Clin Oncol (2013) 1.16
Androgen receptor: structure, role in prostate cancer and drug discovery. Acta Pharmacol Sin (2014) 1.15
An update on PARP inhibitors for the treatment of cancer. Onco Targets Ther (2015) 1.14
Oncogenic activation of ERG: A predominant mechanism in prostate cancer. J Carcinog (2011) 1.13
The diverse heterogeneity of molecular alterations in prostate cancer identified through next-generation sequencing. Asian J Androl (2013) 1.11
Targeting cell cycle and hormone receptor pathways in cancer. Oncogene (2013) 1.10
Molecular pathogenesis and progression of prostate cancer. Semin Oncol (2013) 1.08
PARP inhibition sensitizes to low dose-rate radiation TMPRSS2-ERG fusion gene-expressing and PTEN-deficient prostate cancer cells. PLoS One (2013) 1.06
Correlation of urine TMPRSS2:ERG and PCA3 to ERG+ and total prostate cancer burden. Am J Clin Pathol (2012) 1.05
Heterogeneity in the inter-tumor transcriptome of high risk prostate cancer. Genome Biol (2014) 1.04
Genetic and molecular differences in prostate carcinogenesis between African American and Caucasian American men. Int J Mol Sci (2013) 1.03
Which, when and why? Rational use of tissue-based molecular testing in localized prostate cancer. Prostate Cancer Prostatic Dis (2015) 1.02
Chromoplexy: a new category of complex rearrangements in the cancer genome. Cancer Cell (2013) 1.01
The role of BRCA1 and BRCA2 in prostate cancer. Asian J Androl (2012) 1.00
Modification of the association between obesity and lethal prostate cancer by TMPRSS2:ERG. J Natl Cancer Inst (2013) 0.97
Novel dual-color immunohistochemical methods for detecting ERG-PTEN and ERG-SPINK1 status in prostate carcinoma. Mod Pathol (2013) 0.97
Epigenomic alterations in localized and advanced prostate cancer. Neoplasia (2013) 0.96
Genomic "Dark Matter" in Prostate Cancer: Exploring the Clinical Utility of ncRNA as Biomarkers. Front Genet (2012) 0.96
ERG is a critical regulator of Wnt/LEF1 signaling in prostate cancer. Cancer Res (2013) 0.94
The oncogene ERG: a key factor in prostate cancer. Oncogene (2015) 0.93
Novel RNA hybridization method for the in situ detection of ETV1, ETV4, and ETV5 gene fusions in prostate cancer. Appl Immunohistochem Mol Morphol (2014) 0.93
HOXB13 G84E-related familial prostate cancers: a clinical, histologic, and molecular survey. Am J Surg Pathol (2014) 0.92
Evaluation of tissue PCA3 expression in prostate cancer by RNA in situ hybridization--a correlative study with urine PCA3 and TMPRSS2-ERG. Mod Pathol (2013) 0.90
A comparison of isolated circulating tumor cells and tissue biopsies using whole-genome sequencing in prostate cancer. Oncotarget (2015) 0.90
Interplay between genomic alterations and androgen receptor signaling during prostate cancer development and progression. Horm Cancer (2013) 0.89
Resistance emerges to second-generation antiandrogens in prostate cancer. Cancer Discov (2013) 0.89
Analytical platform evaluation for quantification of ERG in prostate cancer using protein and mRNA detection methods. J Transl Med (2015) 0.89
Overexpression of ETV4 is oncogenic in prostate cells through promotion of both cell proliferation and epithelial to mesenchymal transition. Oncogenesis (2012) 0.88
Improvements in Radiographic Progression-Free Survival Stratified by ERG Gene Status in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone Acetate. Clin Cancer Res (2015) 0.88
Recurrent rearrangements in prostate cancer: causes and therapeutic potential. Curr Drug Targets (2013) 0.88
Androgen receptor CAG repeat polymorphism and risk of TMPRSS2:ERG-positive prostate cancer. Cancer Epidemiol Biomarkers Prev (2014) 0.88
Molecular evidence that invasive adenocarcinoma can mimic prostatic intraepithelial neoplasia (PIN) and intraductal carcinoma through retrograde glandular colonization. J Pathol (2015) 0.87
ERG overexpression and PTEN status predict capsular penetration in prostate carcinoma. Prostate (2013) 0.86
Nucleotide resolution analysis of TMPRSS2 and ERG rearrangements in prostate cancer. J Pathol (2013) 0.86
ERG rearrangement and protein expression in the progression to castration-resistant prostate cancer. Prostate Cancer Prostatic Dis (2014) 0.85
Low Frequency of the ERG Oncogene Alterations in Prostate Cancer Patients from India. J Cancer (2013) 0.85
Androgen receptor gene rearrangements: new perspectives on prostate cancer progression. Curr Drug Targets (2013) 0.85
Predominance of ERG-negative high-grade prostate cancers in African American men. Mol Clin Oncol (2014) 0.85
Gene fusions in soft tissue tumors: Recurrent and overlapping pathogenetic themes. Genes Chromosomes Cancer (2015) 0.85
The TMPRSS2-ERG Gene Fusion Blocks XRCC4-Mediated Nonhomologous End-Joining Repair and Radiosensitizes Prostate Cancer Cells to PARP Inhibition. Mol Cancer Ther (2015) 0.83
Loss of CDKN1B/p27Kip1 expression is associated with ERG fusion-negative prostate cancer, but is unrelated to patient prognosis. Oncol Lett (2013) 0.83
Evaluation of ERG responsive proteome in prostate cancer. Prostate (2013) 0.83
Personalized management in low-risk prostate cancer: the role of biomarkers. Prostate Cancer (2012) 0.82
Dietary lycopene intake and risk of prostate cancer defined by ERG protein expression. Am J Clin Nutr (2016) 0.82
Novel therapies for the treatment of advanced prostate cancer. Curr Treat Options Oncol (2013) 0.82
ERG induces epigenetic activation of Tudor domain-containing protein 1 (TDRD1) in ERG rearrangement-positive prostate cancer. PLoS One (2013) 0.81
Genomic predictors for treatment of late stage prostate cancer. Asian J Androl (2016) 0.81
Obesity and Prostate Cancer Risk According to Tumor TMPRSS2:ERG Gene Fusion Status. Am J Epidemiol (2015) 0.81
DTX3L and ARTD9 inhibit IRF1 expression and mediate in cooperation with ARTD8 survival and proliferation of metastatic prostate cancer cells. Mol Cancer (2014) 0.81
SPOP Mutation Drives Prostate Tumorigenesis In Vivo through Coordinate Regulation of PI3K/mTOR and AR Signaling. Cancer Cell (2017) 0.81
Overexpression of ERG and Wild-Type PTEN Are Associated with Favorable Clinical Prognosis and Low Biochemical Recurrence in Prostate Cancer. PLoS One (2015) 0.80
Prostate adenocarcinomas aberrantly expressing p63 are molecularly distinct from usual-type prostatic adenocarcinomas. Mod Pathol (2014) 0.80
A step toward functionally characterized prostate cancer molecular subtypes. Nat Med (2013) 0.80
Genomic rearrangements in prostate cancer. Curr Opin Urol (2015) 0.80
Specific and redundant activities of ETV1 and ETV4 in prostate cancer aggressiveness revealed by co-overexpression cellular contexts. Oncotarget (2015) 0.80
Sustained Complete Response to Cytotoxic Therapy and the PARP Inhibitor Veliparib in Metastatic Castration-Resistant Prostate Cancer - A Case Report. Front Oncol (2015) 0.79
ERG oncoprotein expression in prostate carcinoma patients of different ethnicities. Mol Clin Oncol (2014) 0.79
Determinants and effects of positive surgical margins after prostatectomy on prostate cancer mortality: a population-based study. BMC Urol (2014) 0.79
Androgen receptor genomic regulation. Transl Androl Urol (2013) 0.79
Assembly of methylated KDM1A and CHD1 drives androgen receptor-dependent transcription and translocation. Nat Struct Mol Biol (2016) 0.79
Functional antagonism of TMPRSS2-ERG splice variants in prostate cancer. Genes Cancer (2014) 0.79
TMPRSS2-ERG fusion promotes prostate cancer metastases in bone. Oncotarget (2016) 0.78
Chromosomal structural variations during progression of a prostate epithelial cell line to a malignant metastatic state inactivate the NF2, NIPSNAP1, UGT2B17, and LPIN2 genes. Cancer Biol Ther (2013) 0.78
Insights into the mechanism of organ-specific cancer metastasis. Cancer Discov (2014) 0.78
Targeted Cancer Therapy: Vital Oncogenes and a New Molecular Genetic Paradigm for Cancer Initiation Progression and Treatment. Int J Mol Sci (2016) 0.77
ERG is specifically associated with ETS-2 and ETV-4, but not with ETS-1, in prostate cancer. Int J Mol Med (2012) 0.77
Interaction of the Androgen Receptor, ETV1, and PTEN Pathways in Mouse Prostate Varies with Pathological Stage and Predicts Cancer Progression. Horm Cancer (2015) 0.77
The molecular basis for ethnic variation and histological subtype differences in prostate cancer. Sci China Life Sci (2013) 0.77
Combined MYC Activation and Pten Loss Are Sufficient to Create Genomic Instability and Lethal Metastatic Prostate Cancer. Cancer Res (2015) 0.77
Downregulation of miR-129 in peripheral blood mononuclear cells is a diagnostic and prognostic biomarker in prostate cancer. Int J Clin Exp Pathol (2015) 0.77
The prognostic significance of combined ERG and androgen receptor expression in patients with prostate cancer managed by androgen deprivation therapy. Cancer Biol Ther (2014) 0.77
ERG oncoprotein inhibits ANXA2 expression and function in prostate cancer. Mol Cancer Res (2014) 0.77
Influence of family history on psychosocial distress and perceived need for treatment in prostate cancer survivors. Fam Cancer (2014) 0.76
Usefulness of a monoclonal ERG/FLI1 antibody for immunohistochemical discrimination of Ewing family tumors. Am J Clin Pathol (2013) 0.76
Epigenomic profiling of prostate cancer identifies differentially methylated genes in TMPRSS2:ERG fusion-positive versus fusion-negative tumors. Clin Epigenetics (2015) 0.76
Immunotherapy and immune evasion in prostate cancer. Cancers (Basel) (2013) 0.76
Reconstitution of the ERG Gene Expression Network Reveals New Biomarkers and Therapeutic Targets in ERG Positive Prostate Tumors. J Cancer (2015) 0.76
Pre-diagnostic circulating sex hormone levels and risk of prostate cancer by ERG tumour protein expression. Br J Cancer (2016) 0.76
Next-gen tissue: preservation of molecular and morphological fidelity in prostate tissue. Am J Transl Res (2015) 0.75
Extended use of Prostate Health Index and percentage of [-2]pro-prostate-specific antigen in Chinese men with prostate specific antigen 10-20 ng/mL and normal digital rectal examination. Investig Clin Urol (2016) 0.75
Obesity and Prostate Cancer: A Focused Update on Active Surveillance, Race, and Molecular Subtyping. Eur Urol (2016) 0.75
Prostate tumor development and androgen receptor function alterations in a new mouse model with ERG overexpression and PTEN inactivation. Cancer Biol Ther (2014) 0.75
Prostate Cancer Genetics: A Review. EJIFCC (2015) 0.75
Effects of Combined Treatment with Ionizing Radiation and the PARP Inhibitor Olaparib in BRCA Mutant and Wild Type Patient-Derived Pancreatic Cancer Xenografts. PLoS One (2016) 0.75
Putative Prostate Cancer Risk SNP in an Androgen Receptor-Binding Site of the Melanophilin Gene Illustrates Enrichment of Risk SNPs in Androgen Receptor Target Sites. Hum Mutat (2015) 0.75
ETS Related Gene mediated Androgen Receptor Aggregation and Endoplasmic Reticulum Stress in Prostate Cancer Development. Sci Rep (2017) 0.75
Cancer statistics, 2010. CA Cancer J Clin (2010) 103.28
Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science (2005) 39.06
Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature (2007) 37.09
The genomic complexity of primary human prostate cancer. Nature (2011) 14.06
Transcriptome sequencing to detect gene fusions in cancer. Nature (2009) 11.63
Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci U S A (2004) 10.99
Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature (2007) 10.94
Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol (2008) 10.91
EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res (2008) 9.29
Integrative molecular concept modeling of prostate cancer progression. Nat Genet (2006) 8.49
TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res (2006) 7.61
A topoisomerase IIbeta-mediated dsDNA break required for regulated transcription. Science (2006) 6.71
TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion. Am J Surg Pathol (2007) 6.09
Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia (2008) 5.92
Prostate cancer. N Engl J Med (2003) 5.91
TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene (2007) 5.79
Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther (2008) 5.78
Nuclear receptor-induced chromosomal proximity and DNA breaks underlie specific translocations in cancer. Cell (2009) 5.74
Chimeric transcript discovery by paired-end transcriptome sequencing. Proc Natl Acad Sci U S A (2009) 5.30
TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer. Cancer Res (2006) 4.99
Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer. Oncogene (2007) 4.81
Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. Nat Med (2010) 4.81
Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. Cancer Res (2009) 4.68
Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer. Cancer Res (2006) 4.50
Androgen-induced TOP2B-mediated double-strand breaks and prostate cancer gene rearrangements. Nat Genet (2010) 3.83
A causal role for ERG in neoplastic transformation of prostate epithelium. Proc Natl Acad Sci U S A (2008) 3.83
Antibody-based detection of ERG rearrangement-positive prostate cancer. Neoplasia (2010) 3.66
Characterization of TMPRSS2:ETV5 and SLC45A3:ETV5 gene fusions in prostate cancer. Cancer Res (2008) 3.59
Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer. J Natl Cancer Inst (2008) 3.55
Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer. Mod Pathol (2007) 3.37
A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer. Cancer Res (2008) 3.35
Induced chromosomal proximity and gene fusions in prostate cancer. Science (2009) 3.31
Pharmacology of novel steroidal inhibitors of cytochrome P450(17) alpha (17 alpha-hydroxylase/C17-20 lyase). J Steroid Biochem Mol Biol (1994) 3.19
Diversity of TMPRSS2-ERG fusion transcripts in the human prostate. Oncogene (2006) 3.09
Three-color FISH analysis of TMPRSS2/ERG fusions in prostate cancer indicates that genomic microdeletion of chromosome 21 is associated with rearrangement. Neoplasia (2006) 3.08
Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer. Cancer Res (2008) 3.02
Expression of TMPRSS2:ERG gene fusion in prostate cancer cells is an important prognostic factor for cancer progression. Cancer Biol Ther (2007) 2.97
ETS family transcription factors collaborate with alternative signaling pathways to induce carcinoma from adult murine prostate cells. Proc Natl Acad Sci U S A (2009) 2.93
A fluorescence in situ hybridization screen for E26 transformation-specific aberrations: identification of DDX5-ETV4 fusion protein in prostate cancer. Cancer Res (2008) 2.87
The role of SPINK1 in ETS rearrangement-negative prostate cancers. Cancer Cell (2008) 2.87
TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer. Cancer Res (2006) 2.83
Therapeutic targeting of SPINK1-positive prostate cancer. Sci Transl Med (2011) 2.83
TMPRSS2 fusions with oncogenic ETS factors in prostate cancer involve unbalanced genomic rearrangements and are associated with HDAC1 and epigenetic reprogramming. Cancer Res (2006) 2.82
Confirmation of the high frequency of the TMPRSS2/ERG fusion gene in prostate cancer. Genes Chromosomes Cancer (2006) 2.69
Gene fusions between TMPRSS2 and ETS family genes in prostate cancer: frequency and transcript variant analysis by RT-PCR and FISH on paraffin-embedded tissues. Mod Pathol (2007) 2.68
Complex patterns of ETS gene alteration arise during cancer development in the human prostate. Oncogene (2007) 2.68
Detection of TMPRSS2-ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer. Clin Cancer Res (2007) 2.63
Heterogeneity of TMPRSS2 gene rearrangements in multifocal prostate adenocarcinoma: molecular evidence for an independent group of diseases. Cancer Res (2007) 2.60
Characterization of TMPRSS2-ERG fusion high-grade prostatic intraepithelial neoplasia and potential clinical implications. Clin Cancer Res (2008) 2.58
Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States. Clin Cancer Res (2009) 2.51
TMPRSS2-ERG gene fusion causing ERG overexpression precedes chromosome copy number changes in prostate carcinomas and paired HGPIN lesions. Neoplasia (2006) 2.48
Frequency of the TMPRSS2:ERG gene fusion is increased in moderate to poorly differentiated prostate cancers. J Clin Pathol (2007) 2.48
A variant TMPRSS2 isoform and ERG fusion product in prostate cancer with implications for molecular diagnosis. Mod Pathol (2007) 2.47
Overexpression of the ETS-related gene, ERG, predicts a worse outcome in acute myeloid leukemia with normal karyotype: a Cancer and Leukemia Group B study. J Clin Oncol (2005) 2.41
Noninvasive detection of TMPRSS2:ERG fusion transcripts in the urine of men with prostate cancer. Neoplasia (2006) 2.39
TMPRSS2-ERG fusion heterogeneity in multifocal prostate cancer: clinical and biologic implications. Urology (2007) 2.28
Heterogeneity of Gleason grade in multifocal adenocarcinoma of the prostate. Cancer (2004) 2.22
TMPRSS2:ERG fusion identifies a subgroup of prostate cancers with a favorable prognosis. Clin Cancer Res (2008) 2.16
SLC45A3-ELK4 is a novel and frequent erythroblast transformation-specific fusion transcript in prostate cancer. Cancer Res (2009) 2.03
25-year prostate cancer control and survival outcomes: a 40-year radical prostatectomy single institution series. J Urol (2006) 1.82
Triggers for genomic rearrangements: insights into genomic, cellular and environmental influences. Nat Rev Genet (2010) 1.82
Evidence of independent origin of multiple tumors from patients with prostate cancer. J Natl Cancer Inst (1998) 1.81
N-myc downstream regulated gene 1 (NDRG1) is fused to ERG in prostate cancer. Neoplasia (2009) 1.68
The long-term clinical impact of biochemical recurrence of prostate cancer 5 or more years after radical prostatectomy. J Urol (2003) 1.64
Comprehensive assessment of DNA copy number alterations in human prostate cancers using Affymetrix 100K SNP mapping array. Genes Chromosomes Cancer (2006) 1.58
Prevalence of TMPRSS2-ERG and SLC45A3-ERG gene fusions in a large prostatectomy cohort. Mod Pathol (2010) 1.55
Chromosomal anomalies in prostatic intraepithelial neoplasia and carcinoma detected by fluorescence in situ hybridization. Cancer Res (1995) 1.52
Molecular genetic analyses of the TMPRSS2-ERG and TMPRSS2-ETV1 gene fusions in 50 cases of prostate cancer. Oncol Rep (2007) 1.43
A comparison of the morphological features of cancer arising in the transition zone and in the peripheral zone of the prostate. J Urol (1991) 1.40
Long-term outcome following radical prostatectomy in men with clinical stage T3 prostate cancer. J Urol (2006) 1.35
Androgen-induced TMPRSS2:ERG fusion in nonmalignant prostate epithelial cells. Cancer Res (2010) 1.30
Allelic loss in locally metastatic, multisampled prostate cancer. Cancer Res (1994) 1.24
Bioinformatics approaches in the study of cancer. Curr Mol Med (2007) 1.23
A working group classification of focal prostate atrophy lesions. Am J Surg Pathol (2006) 1.13
Bioinformatics approach leads to the discovery of the TMPRSS2:ETS gene fusion in prostate cancer. Lab Invest (2006) 0.90
ETS-TMPRSS2 fusion gene products in prostate cancer. Cancer Biol Ther (2006) 0.87
Microdeletion and concurrent translocation associated with a complex TMPRSS2:ERG prostate cancer gene fusion. Genes Chromosomes Cancer (2007) 0.83
Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science (2005) 39.06
The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature (2002) 18.30
ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia (2004) 17.08
Development of human protein reference database as an initial platform for approaching systems biology in humans. Genome Res (2003) 14.79
The Sorghum bicolor genome and the diversification of grasses. Nature (2009) 14.62
EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci U S A (2003) 13.68
ProbeMatch: rapid alignment of oligonucleotides to genome allowing both gaps and mismatches. Bioinformatics (2009) 13.34
Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature (2009) 12.58
The mutational landscape of lethal castration-resistant prostate cancer. Nature (2012) 11.82
Transcriptome sequencing to detect gene fusions in cancer. Nature (2009) 11.63
Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature (2007) 10.94
Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia (2007) 10.74
TEAD mediates YAP-dependent gene induction and growth control. Genes Dev (2008) 9.88
Large-scale meta-analysis of cancer microarray data identifies common transcriptional profiles of neoplastic transformation and progression. Proc Natl Acad Sci U S A (2004) 9.42
Integrative molecular concept modeling of prostate cancer progression. Nat Genet (2006) 8.49
Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature (2012) 8.03
TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res (2006) 7.61
Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science (2008) 7.59
Autoantibody signatures in prostate cancer. N Engl J Med (2005) 7.56
Meta-analysis of microarrays: interstudy validation of gene expression profiles reveals pathway dysregulation in prostate cancer. Cancer Res (2002) 7.29
Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell (2009) 7.09
An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. Cancer Cell (2010) 6.76
Transcriptome sequencing across a prostate cancer cohort identifies PCAT-1, an unannotated lincRNA implicated in disease progression. Nat Biotechnol (2011) 6.54
The emergence of lncRNAs in cancer biology. Cancer Discov (2011) 6.32
Genomic landscape of non-small cell lung cancer in smokers and never-smokers. Cell (2012) 6.09
TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion. Am J Surg Pathol (2007) 6.09
Recurrent gene fusions in prostate cancer. Nat Rev Cancer (2008) 6.08
Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell (2005) 6.04
The transcriptional network that controls growth arrest and differentiation in a human myeloid leukemia cell line. Nat Genet (2009) 6.02
A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth. Mol Cell (2007) 5.99
Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia (2008) 5.92
Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program. Cancer Res (2004) 5.88
Personalized oncology through integrative high-throughput sequencing: a pilot study. Sci Transl Med (2011) 5.82
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. N Engl J Med (2015) 5.39
Chimeric transcript discovery by paired-end transcriptome sequencing. Proc Natl Acad Sci U S A (2009) 5.30
EML4-ALK fusion lung cancer: a rare acquired event. Neoplasia (2008) 5.22
miR-24 Inhibits cell proliferation by targeting E2F2, MYC, and other cell-cycle genes via binding to "seedless" 3'UTR microRNA recognition elements. Mol Cell (2009) 5.22
alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. JAMA (2002) 5.07
TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer. Cancer Res (2006) 4.99
Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. Nat Med (2010) 4.81
Integrative analysis of the cancer transcriptome. Nat Genet (2005) 4.44
Integrative genomics analysis reveals silencing of beta-adrenergic signaling by polycomb in prostate cancer. Cancer Cell (2007) 4.43
Expressed pseudogenes in the transcriptional landscape of human cancers. Cell (2012) 4.22
Probabilistic model of the human protein-protein interaction network. Nat Biotechnol (2005) 3.99
Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat Genet (2013) 3.96
A polycomb repression signature in metastatic prostate cancer predicts cancer outcome. Cancer Res (2007) 3.82
Multiplex biomarker approach for determining risk of prostate-specific antigen-defined recurrence of prostate cancer. J Natl Cancer Inst (2003) 3.73
Antibody-based detection of ERG rearrangement-positive prostate cancer. Neoplasia (2010) 3.66
Characterization of TMPRSS2:ETV5 and SLC45A3:ETV5 gene fusions in prostate cancer. Cancer Res (2008) 3.59
Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer. J Natl Cancer Inst (2008) 3.55
Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer. Cancer Cell (2011) 3.53
Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov (2011) 3.43
The long noncoding RNA SChLAP1 promotes aggressive prostate cancer and antagonizes the SWI/SNF complex. Nat Genet (2013) 3.39
Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer. Mod Pathol (2007) 3.37
A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer. Cancer Res (2008) 3.35
Induced chromosomal proximity and gene fusions in prostate cancer. Science (2009) 3.31
Identification of targetable FGFR gene fusions in diverse cancers. Cancer Discov (2013) 3.13
Molecular concepts analysis links tumors, pathways, mechanisms, and drugs. Neoplasia (2007) 3.06
Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer. Cancer Res (2008) 3.02
ETS gene fusions in prostate cancer: from discovery to daily clinical practice. Eur Urol (2009) 2.91
Mining for regulatory programs in the cancer transcriptome. Nat Genet (2005) 2.88
A fluorescence in situ hybridization screen for E26 transformation-specific aberrations: identification of DDX5-ETV4 fusion protein in prostate cancer. Cancer Res (2008) 2.87
The role of SPINK1 in ETS rearrangement-negative prostate cancers. Cancer Cell (2008) 2.87
Therapeutic targeting of SPINK1-positive prostate cancer. Sci Transl Med (2011) 2.83
Functionally recurrent rearrangements of the MAST kinase and Notch gene families in breast cancer. Nat Med (2011) 2.77
ChimeraScan: a tool for identifying chimeric transcription in sequencing data. Bioinformatics (2011) 2.74
Fluorescence in situ hybridization study shows association of PTEN deletion with ERG rearrangement during prostate cancer progression. Mod Pathol (2009) 2.69
Genome-wide analysis of cancer/testis gene expression. Proc Natl Acad Sci U S A (2008) 2.66
Expression of CXCR4 and CXCL12 (SDF-1) in human prostate cancers (PCa) in vivo. J Cell Biochem (2003) 2.62
Urine TMPRSS2:ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA. Sci Transl Med (2011) 2.62
Heterogeneity of TMPRSS2 gene rearrangements in multifocal prostate adenocarcinoma: molecular evidence for an independent group of diseases. Cancer Res (2007) 2.60
JAGGED1 expression is associated with prostate cancer metastasis and recurrence. Cancer Res (2004) 2.59
New class of microRNA targets containing simultaneous 5'-UTR and 3'-UTR interaction sites. Genome Res (2009) 2.56
Identification of GATA3 as a breast cancer prognostic marker by global gene expression meta-analysis. Cancer Res (2005) 2.55
Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States. Clin Cancer Res (2009) 2.51
Discovery of non-ETS gene fusions in human prostate cancer using next-generation RNA sequencing. Genome Res (2010) 2.50
Changes in differential gene expression because of warm ischemia time of radical prostatectomy specimens. Am J Pathol (2002) 2.50
Activation of mitogen-activated protein kinase in estrogen receptor alpha-positive breast cancer cells in vitro induces an in vivo molecular phenotype of estrogen receptor alpha-negative human breast tumors. Cancer Res (2006) 2.46
HPeak: an HMM-based algorithm for defining read-enriched regions in ChIP-Seq data. BMC Bioinformatics (2010) 2.41
Noninvasive detection of TMPRSS2:ERG fusion transcripts in the urine of men with prostate cancer. Neoplasia (2006) 2.39
Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva). Cancer Res (2005) 2.31
Identification of recurrent NAB2-STAT6 gene fusions in solitary fibrous tumor by integrative sequencing. Nat Genet (2013) 2.30
A genome-wide characterization of microRNA genes in maize. PLoS Genet (2009) 2.23
Detection of somatic copy number alterations in cancer using targeted exome capture sequencing. Neoplasia (2011) 2.21
A p53/miRNA-34 axis regulates Snail1-dependent cancer cell epithelial-mesenchymal transition. J Cell Biol (2011) 2.19
Integrative analysis of genomic aberrations associated with prostate cancer progression. Cancer Res (2007) 2.14
Alpha-Methylacyl-CoA racemase: a novel tumor marker over-expressed in several human cancers and their precursor lesions. Am J Surg Pathol (2002) 2.10
FIZZ1 stimulation of myofibroblast differentiation. Am J Pathol (2004) 2.06
Prognostic meta-signature of breast cancer developed by two-stage mixture modeling of microarray data. BMC Genomics (2004) 2.02
Characterization of KRAS rearrangements in metastatic prostate cancer. Cancer Discov (2011) 2.02
A germline DNA polymorphism enhances alternative splicing of the KLF6 tumor suppressor gene and is associated with increased prostate cancer risk. Cancer Res (2005) 2.02
Beyond PSA: the next generation of prostate cancer biomarkers. Sci Transl Med (2012) 2.00